Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway.
about
The Suprachoroidal Route in Glaucoma SurgeryProspects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivoInfluence of Age on Ocular Biomechanical Properties in a Canine Glaucoma Model with ADAMTS10 MutationCritical evaluation of latanoprostene bunod in the treatment of glaucomaEnhancement of scleral macromolecular permeability with prostaglandinsProlonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates.Uveoscleral outflow.Therapeutic potential of prostaglandin analogues in glaucoma.Latanoprost-induced changes in rat intraocular pressure: direct or indirect?Prostaglandin-associated periorbitopathy in latanoprost usersDecreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analoguesExpression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye.Functional dichotomy: glutathione and vitamin E in homeostasis relevant to primary open-angle glaucoma.In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytesCharacterization of uveoscleral outflow in enucleated porcine eyes perfused under constant pressure.Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins, and understanding the pathophysiology of presbyopia interrogating Mother Nature: asking why, asking how, recognizing the signs, foProstanoids in the therapy of glaucoma.Topical drug therapy in glaucoma.The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes.Travoprost in the management of open-angle glaucoma and ocular hypertensionUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reduction.Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides.A review of the use of latanoprost for glaucoma since its launch.Pharmacology of topical prostaglandin F2 α analogs and their place in the treatment of glaucoma in small animals.Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.Unconventional aqueous humor outflow: A review.Bimatoprost-induced late-onset choroidal detachment after trabeculectomy: A case report and review of the literature.Effect of latanoprost and timolol on the histopathology of the human conjunctiva.Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures.Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway.Deepening of eyelid superior sulcus during topical travoprost treatment.Prostaglandins E1 and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction.Effect of latanoprost on cultured porcine corneal stromal cells.[Suprachoroidal minimally invasive glaucoma surgery : Procedures and clinical outcome].Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo.
P2860
Q26745651-7242CE94-099F-4F00-B90F-84D02368EAEEQ27024271-51F4DA7D-FD15-431C-834C-E2B32F39E8FBQ27342641-C617EC75-8407-4C60-A92F-AFD9BDB3A751Q28077208-7653C250-4BDC-499E-8BF6-E22F708478CDQ28345276-DE2139D2-70F2-47E2-B1AF-922A2DAE9E87Q33792019-5EA82D38-576F-47B5-8C2D-9E8A0D99B5C1Q34057640-51F6563E-E314-44B6-8E12-1E18497F3D09Q34204357-8DEDFBD1-7510-4213-A981-AFF865727BFDQ34309976-BEB8F5AF-C438-4EA2-BED0-CA510215AD63Q34823605-339FE043-91DC-41B7-A702-D684D93C3485Q35189170-5DBEF938-6ACA-495B-9DC2-9651DA9A8F65Q35221250-7B3D47A1-70DA-42F3-8434-9891ED394A7AQ35795259-DDC2E5C2-0C28-43BD-A4F2-BF9211C4EEFCQ35860207-57A6EF11-AB3D-41ED-9722-6C960FB2BA59Q35920293-ED470668-8A53-4044-99C9-7E63F20282BFQ36403804-FA9FBB7D-9C76-49E3-9365-182EA84E918EQ36580774-89EB395D-08F7-4149-9088-83E08AD07C5BQ36623753-057182F8-3DAF-46BD-8D6D-868258B49A43Q37222635-2E281C23-59A0-413D-BFC6-F2643876B8EBQ37236653-CADF489B-1B83-4B09-90F4-CFFE806A41C4Q37336299-AF257BD0-994A-4A5A-BF5C-0405EDEC1625Q37636153-1960D1E9-8721-4CCC-AB1E-26CA2C4EBBB7Q37986149-51FF01A6-379E-4864-9F86-D575E57C1A77Q38250396-4B75624F-BA96-4C9B-8A0B-355C54FF5955Q38443489-8D1CBAC1-87E8-4C76-9D83-206F324695A9Q38724447-21420EBD-40A8-4EF9-A15C-5C5E06B5879DQ39115520-BEA82204-E614-4516-961D-B6A7ED613C2CQ43196405-5AC47FA6-CD54-46B2-88CD-F2BD7342E8A2Q43681101-6A4C3DEE-6E59-4D58-B69C-760F4B1307A6Q45068040-74AB774C-B8B9-4326-A975-D0FEF657C242Q45872509-0C54EB5F-08DC-478C-B68F-6E1C52BCED69Q46068028-D7962E5F-82A6-4A23-8DDC-4A946E7C9A27Q46658201-DF90BF4A-2A83-4B27-8335-11D566F72BA6Q46775923-39F960A7-46CA-4826-8916-DD139D02F4C9Q50129666-408274E7-507E-4DC2-89B3-0D99FD599B7BQ51191793-BB419FBD-D3B6-433C-97F0-00731B2D8432
P2860
Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Topical prostaglandin F2alpha ...... y uveoscleral outflow pathway.
@en
type
label
Topical prostaglandin F2alpha ...... y uveoscleral outflow pathway.
@en
prefLabel
Topical prostaglandin F2alpha ...... y uveoscleral outflow pathway.
@en
P2093
P1433
P1476
Topical prostaglandin F2alpha ...... y uveoscleral outflow pathway.
@en
P2093
B T Gabelt
J D Lindsey
P L Kaufman
R N Weinreb
P304
P356
10.1001/ARCHOPHT.117.6.794
P407
P577
1999-06-01T00:00:00Z